Risk of hip or vertebral fracture in stroke survivors using anti-spasticity medications: A case-control study

Journal of Outcomes Research

Volumn 10, Issue 1-11, 2006, Pages 1-11

  Nichol, Michael B ^a   Shi, Sheng G ^a   Knight, Tara K ^a   Esquenazi, Alberto ^b,c   Barron, Richard ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c Gait and Motion Analysis Laboratory   (United States)

^d ALLERGAN INC   (United States)

Author keywords

Anti spasticity medication; Fractures; Spasticity

Indexed keywords

BACLOFEN; CLONAZEPAM; CLONIDINE; CLORAZEPATE; CYPROHEPTADINE; DANTROLENE; DIAZEPAM; DRONABINOL; LAMOTRIGINE; ORPHENADRINE; RILUZOLE; SPASMOLYTIC AGENT; TIZANIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; STROKE; VERTEBRA FRACTURE;

EID: 33646029947     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Smith R, Fordham R. Economics of fall prevention programs: evidence and research priorities. Expert Review of Pharmacoeconomics and Outcomes Research 2001; 1: 59-67.
2. Mulley G, Espley A. Hip fracture after hemiplegia. Postgraduate Medical Journal 1979; 55: 264-265.
3. Ramnemark A, Nyberg L, Borssen B et al. Fractures after stroke. Osteoporosis International 1998; 8: 92-95.
4. Ramnemark A, Nilsson M, Borssen B et al. Stroke, a major and increasing risk factor for femoral neck fracture. Stroke 2000; 31: 1572-1577.
5. DeVincenzo D, Watkins S. Accidental falls in a rehabilitation setting. Rehabilitation Nursing 1987; 12: 248-252.
6. Koval K, Zuckerman J. Functional recovery after fracture of the hip. Journal of Bone and Joint Surgery. American Volume 1994; 76A: 751-758.
7. Youm T, Koval K, Zuckerman J. The economic impact of geriatric hip fractures. American Journal of Orthopedics 1999; 28: 423-428.
8. Mayer N, Esquenazi A, Childers M. Common patterns of clinical motor dysfunction. Muscle & Nerve. Supplement 1997; 6: S21-S35.
9. Barnes M. Spasticity: a rehabilitation challenge in the elderly. Gerontology 2001; 47: 295-299.
10. Simpson D. Treatment of spasticity with botulinum toxin. Muscle & Nerve 2000; 23: 447-449.
11. Goldstein E. Spasticity management: an overview. Journal of Child Neurology 2001; 16: 16-23.
12. Gracies J, Nance P, Elovic E et al. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle & Nerve. Supplement 1997; 6: S92-S120.
13. O'Brien C, Seeberger L, Smith D. Spasticity after stroke. Epidemiology and optimal treatment. Drugs & Aging 1996; 9: 332-340.
14. Wallace J. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994; 44(11 Suppl 9): S60-S80.
15. Cox D, Snell E. The Analysis of Binary Data, 2nd ed. London, UK: Chapman and Hall, 1989.
16. Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika 1991; 7-8: 691-692.